{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:59:28Z","timestamp":1756382368212,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19fk0210040."],"award-info":[{"award-number":["JP19fk0210040."]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12328-020-01215-3","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T19:02:46Z","timestamp":1599073366000},"page":"1289-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease"],"prefix":"10.1007","volume":"13","author":[{"given":"Maki","family":"Tobari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-1709","authenticated-orcid":false,"given":"Etsuko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Taniai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koening AB, Abdelatif D, Fazel Y, et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"issue":"Suppl 19","key":"1215_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00535-008-2262-x","volume":"44","author":"E Hashimoto","year":"2009","unstructured":"Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl 19):89\u201395.","journal-title":"J Gastroenterol"},{"key":"1215_CR3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00535-010-0237-1","volume":"45","author":"K Tokushige","year":"2010","unstructured":"Tokushige K, Hashimoto E, Yatsuji S, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960\u20137.","journal-title":"J Gastroenterol"},{"key":"1215_CR4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cgh.2011.01.023","volume":"9","author":"K Yasui","year":"2011","unstructured":"Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428\u201333.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1215_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1872-034X.2011.00872.x","volume":"42","author":"E Hashimoto","year":"2012","unstructured":"Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res. 2012;42:1\u201314.","journal-title":"Hepatol Res"},{"key":"1215_CR6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/hepr.12372","volume":"45","author":"K Tokushige","year":"2015","unstructured":"Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma based on cryptogenic liver disease: the most common non-viral hepatocellular carcinoma in patients aged over 80years. Hepatol Res. 2015;45:441\u20137.","journal-title":"Hepatol Res"},{"key":"1215_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.28368","volume":"63","author":"F Piscaglia","year":"2016","unstructured":"Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827.","journal-title":"Hepatology"},{"key":"1215_CR8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jgh.14867","volume":"35","author":"M Tobari","year":"2020","unstructured":"Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35:862\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1215_CR9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0168-8278(02)00099-5","volume":"37","author":"M Shimada","year":"2002","unstructured":"Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154\u201360.","journal-title":"J Hepatol"},{"key":"1215_CR10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460\u20138.","journal-title":"Gastroenterology"},{"key":"1215_CR11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625\u201338.","journal-title":"N Engl J Med."},{"key":"1215_CR12","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19236","author":"M Tobari","year":"2020","unstructured":"Tobari M, Hashimoto E. Characteristic features of nonalcoholic fatty liver disease in Japan with a focus on the roles of age, sex and body mass index. Gut Liver. 2020. https:\/\/doi.org\/10.5009\/gnl19236.","journal-title":"Gut Liver"},{"key":"1215_CR13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6603932","volume":"97","author":"SC Larsson","year":"2007","unstructured":"Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005\u20138.","journal-title":"Br J Cancer"},{"key":"1215_CR14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1001\/archinte.166.17.1871","volume":"166","author":"M Inoue","year":"2006","unstructured":"Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871\u20137.","journal-title":"Arch Intern Med"},{"key":"1215_CR15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gut.2004.052167","volume":"54","author":"JA Davila","year":"2005","unstructured":"Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533\u20139.","journal-title":"Gut"},{"key":"1215_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","volume":"4","author":"HB El-Serag","year":"2006","unstructured":"El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369\u201380.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1215_CR17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jdiacomp.2010.06.004","volume":"24","author":"H Noto","year":"2010","unstructured":"Noto H, Osame K, Sasazuki T, et al. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complicat. 2010;24:345\u201353.","journal-title":"J Diabetes Complicat"},{"key":"1215_CR18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/jjco\/hyu108","volume":"44","author":"K Tanaka","year":"2014","unstructured":"Tanaka K, Tsuji I, Tamakoshi A, et al. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44:986\u201399.","journal-title":"Jpn J Clin Oncol"},{"key":"1215_CR19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","volume":"68","author":"R Younes","year":"2018","unstructured":"Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018;68:326\u201334.","journal-title":"J Hepatol"},{"key":"1215_CR20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/gut.2009.199661","volume":"59","author":"F Stickel","year":"2010","unstructured":"Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303\u20137.","journal-title":"Gut"},{"key":"1215_CR21","doi-asserted-by":"crossref","first-page":"12945","DOI":"10.3748\/wjg.v20.i36.12945","volume":"20","author":"P Dongiovanni","year":"2014","unstructured":"Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol. 2014;20:12945\u201355.","journal-title":"World J Gastroenterol"},{"key":"1215_CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","volume":"140","author":"EJ Park","year":"2010","unstructured":"Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197\u2013208.","journal-title":"Cell"},{"key":"1215_CR23","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2014.10.048","volume":"62","author":"M Krawczyk","year":"2015","unstructured":"Krawczyk M, Stokes CS, Romeo S, et al. HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J Hepatol. 2015;62:980\u20131.","journal-title":"J Hepatol."},{"key":"1215_CR24","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","volume":"7","author":"B Donati","year":"2017","unstructured":"Donati B, Dongiovanni P, Romeo S, et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017;7:4492.","journal-title":"Sci Rep"},{"key":"1215_CR25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hep.21684","volume":"46","author":"V Paradis","year":"2007","unstructured":"Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology. 2007;46:140\u20136.","journal-title":"Hepatology"},{"key":"1215_CR26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cgh.2014.05.023","volume":"13","author":"S Agrawal","year":"2015","unstructured":"Agrawal S, Agarwal S, Arnason T, et al. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015;13:1221\u2013300.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1215_CR27","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1053\/j.gastro.2009.07.061","volume":"137","author":"S Dokmak","year":"2009","unstructured":"Dokmak S, Paradis V, Vilgrain V, et al. A single-centersurgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698\u2013705.","journal-title":"Gastroenterology"},{"key":"1215_CR28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/PAS.0b013e3181f31caa","volume":"34","author":"M Salomao","year":"2010","unstructured":"Salomao M, Yu WM, Brown RS, et al. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virusrelated cirrhosis with associated NAFLD\/NASH. Am J Surg Pathol. 2010;34:1630\u20136.","journal-title":"Am J Surg Pathol"},{"key":"1215_CR29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.humpath.2011.07.005","volume":"43","author":"M Salomao","year":"2012","unstructured":"Salomao M, Remotti H, Vaughan R, et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol. 2012;43:737\u201346.","journal-title":"Hum Pathol"},{"key":"1215_CR30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hepr.13203","volume":"48","author":"M Taniai","year":"2018","unstructured":"Taniai M, Hashimoto E, Tobari M, et al. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: a multicenter study using immunohistochemical analysis of adenoma-related markers. Hepatol Res. 2018;48:947\u201355.","journal-title":"Hepatol Res"},{"key":"1215_CR31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00535-015-1050-7","volume":"50","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364\u201377.","journal-title":"J Gastroenterol"},{"key":"1215_CR32","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity(EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity(EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol."},{"key":"1215_CR33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver disease. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"1215_CR34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565\u201375.","journal-title":"Hepatology"},{"key":"1215_CR35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2013.09.015","volume":"60","author":"TL Berentzen","year":"2014","unstructured":"Berentzen TL, Gamborg M, Holst C, et al. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol. 2014;60:325\u201330.","journal-title":"J Hepatol"},{"key":"1215_CR36","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/cncr.28832","volume":"120","author":"JA Flemming","year":"2014","unstructured":"Flemming JA, Yang JD, Vittinghoff E, et al. Risk prediction of hepatocellular carcinoma in patients with Chirrhosis: The ADRESS-HCC risk model. Cancer. 2014;120:3485\u201393.","journal-title":"Cancer"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01215-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-020-01215-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01215-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:39:02Z","timestamp":1630539542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-020-01215-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01215-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor Katsutoshi Tokushige received research funding from Sumitomo Dainippon Pharma; Astellas Pharma; Eisai; TAIHO Pharmaceutical; Chugai Pharmaceutical; Daiichi Sankyo Pharmaceutical; AbbVie GK; Takeda Pharmaceutical Company; Asahi Kasei Corporation; AJINOMOTO; and Otsuka Pharmaceutical. The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}